| abstract |
The present invention is directed to novel diaminothiazoles of formula (I): these compounds inhibit cyclin-dependent kinase 4 (Cdk4) and are selective for Cdk2 and Cdk1. These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, particularly solid cancer. The invention also relates to pharmaceutical compositions comprising such compounds and to the preparation of a medicament for the treatment or control of cancer, most particularly for the treatment or control of breast, lung, colon and prostate tumors. Also directed to their use in. |